Pro Medicus Limited (ASX: PME) has secured a 5-year contract worth A$23 million with the University of Maryland Medical System, delivered through its wholly-owned US subsidiary, Visage Imaging, Inc. The Pro Medicus company announcement was released on 8 Apr 2026.
Figure 1: Pro Medicus Limited branding representing the healthcare imaging technology provider [Courtesy: LinkedIn]
The contract covers the deployment of the Visage 7 Enterprise Imaging Platform across the UMMS network, including Visage 7 Viewer and Visage 7 Workflow. It will be implemented entirely in the cloud, on a transaction-based licensing model with potential upside.
Pro Medicus and UMMS: A Deal Built on Cloud-First Imaging
The University of Maryland Medical System delivers comprehensive health care services throughout Maryland. It includes collaboration with specialists from the University of Maryland School of Medicine.
The UMMS network spans the University of Maryland Medical Center, the Marlene and Stewart Greenebaum Comprehensive Cancer Center, the University of Maryland Children’s Hospital, and the world-renowned R Adams Cowley Shock Trauma Center.
Figure 2: University of Maryland Medical Center signage, part of the UMMS network [Courtesy: UMMS Foundation]
The Platform at the Centre of This Pro Medicus Company Announcement
The Visage 7 Enterprise Imaging Platform will serve as a single, unified imaging platform for diagnostic interpretation across UMMS. The deployment is cloud-based and draws on Visage Imaging’s established implementation process.
Planning for the rollout will commence immediately. Go-live is targeted for early in the 2027 calendar year.
What the CEO Said and Why the Pipeline Is Being Watched
Pro Medicus CEO Dr Sam Hupert spoke directly to the significance of this Pro Medicus company news for the North American market.
“UMMS provides cutting-edge, innovative patient care across the state of Maryland,” said Dr Hupert. “They join an ever growing list of Visage 7 clients to opt for our fully cloud-based platform, which, as a result of our CloudPACS strategy, is becoming the standard in the North American healthcare IT market.”
Figure 3: Pro Medicus CEO Dr Sam Hupert [Courtesy: AFR]
A Global Radiologist Shortage Is Driving Demand
Dr Hupert also addressed the structural tailwind behind this Pro Medicus company announcement and deals like it.
“The global shortage of radiologists is driving healthcare institutions to adopt enterprise imaging platforms that maximise radiologist efficiency and subspecialty workflows with the added security and scalability of the cloud,” he said. Dr Hupert added, “Our pipeline remains strong and spans all market segments.”
Transaction Model Offers More Than the Headline Figure
The contract is structured on a transactional licensing model, which means revenue is tied to actual usage across the UMMS network. This structure carries potential upside beyond the stated A$23 million contract value.
Pro Medicus quarterly updates have consistently reflected the Company’s preference for this model. It aligns revenue with clinical activity and positions the Company to benefit as imaging volumes grow across a client’s network.
PME Share Price
Pro Medicus Limited (ASX: PME) is currently trading at A$130.260 per share, with a market capitalisation of A$12.74 billion. The 52-week range stands at A$107.750 to A$336.000 per share.
Figure 4: Pro Medicus Limited (ASX: PME) one-year share price performance chart [Courtesy: ASX]
Industry Outlook
The global health imaging software market continues to expand as hospital networks migrate away from legacy on-premise systems toward cloud-native platforms. The radiologist shortage across North America is accelerating this transition, with enterprise imaging solutions increasingly seen as critical infrastructure rather than optional IT investment.
Pro Medicus quarterly updates have reflected consistent contract momentum across academic medical centres, health systems, and community hospital networks. The UMMS contract is consistent with this broader trend of large US health networks adopting unified, cloud-based imaging platforms.
Future Direction and Impact on PME Investors
For investors following Pro Medicus company news, this contract adds A$23 million in contracted revenue over five years. The transactional model means actual revenue could exceed this figure if imaging volumes across UMMS grow during the contract term.
The go-live target of early 2027 means this deal will begin contributing to Pro Medicus quarterly updates from that period onward. With the pipeline described as strong across all market segments, this Pro Medicus company announcement is likely to be one of several contract wins investors will track through the remainder of FY2026 and into FY2027.
Frequently Asked Questions
Q1. What is the Pro Medicus and UMMS contract about?
Ans. Pro Medicus signed a 5-year contract with the UMMS to deploy the Visage 7 Enterprise Imaging Platform across the UMMS network in the cloud.
Q2. What products are covered under this Pro Medicus company announcement?
Ans. The contract covers Visage 7 Viewer and Visage 7 Workflow, deployed as a unified cloud-based enterprise imaging platform.
Q3. When will the Visage 7 platform go live at UMMS?
Ans. Go-live is targeted for early in the 2027 calendar year, with rollout planning commencing immediately.
Q4. What is the revenue model for this contract?
Ans. The contract is based on a transactional licensing model, which carries potential upside beyond the A$23 million stated value.
Q5. What did the Pro Medicus CEO say about the deal?
Ans. Dr Sam Hupert said UMMS joins a growing list of Visage 7 clients choosing the fully cloud-based platform, and that the Company’s pipeline remains strong across all market segments.
Disclaimer
This article is intended for informational purposes only and does not constitute financial or investment advice. All content is based on the ASX announcement released by Pro Medicus Limited on 8 Apr 2026 and supplementary publicly available sources. Share price and market capitalisation data reflect figures provided at the time of publication. Investing in securities involves risk. Readers should conduct their own research and seek independent financial advice before making any investment decisions. Colitco does not hold any position in the companies or organisations mentioned.
Sources
https://www.asx.com.au/markets/company/PME
Last modified: April 9, 2026
